Background/Aims: To review the main results of intervention trials which showed the efficacy of periconceptional folic acid-containing multivitamin and folic acid supplementation in the prevention of neural-tube defects (NTD). Methods and Results: The main findings of 5 intervention trials are known: (i) the efficacy of a multivitamin containing 0.36 mg folic acid in a UK nonrandomized controlled trial resulted in an 83–91% reduction in NTD recurrence, while the results of the Hungarian (ii) randomized controlled trial and (iii) cohort-controlled trial using a multivitamin containing 0.8 mg folic acid showed 93 and 89% reductions in the first occurrence of NTD, respectively. On the other hand, (iv) another multicenter randomized controlled trial proved a 71% efficacy of 4 mg folic acid in the reduction of recurrent NTD, while (v) a public health-oriented Chinese-US trial showed a 41–79% reduction in the first occurrence of NTD depending on the incidence of NTD. Conclusions: Translational application of these findings could result in a breakthrough in the primary prevention of NTD, but so far this is not widely applied in practice. The benefits and drawbacks of 4 main possible uses of periconceptional folic acid/multivitamin supplementation, i.e. (i) dietary intake, (ii) periconceptional supplementation, (iii) flour fortification, and (iv) the recent attempt for the use of combination of oral contraceptives with 6S-5-methytetrahydrofolate (methylfolate), are discussed. Obviously, prevention of NTD is much better than the frequent elective termination of pregnancies after prenatal diagnosis of NTD fetuses.

Keywords:
Folic acid, Methylfolate, Multivitamins, Prevention, Elective termination of affected fetuses, Neural-tube defects
1.
Smithells RW, Sheppard S, Wild J, Schorah CJ: Prevention of neural tube defect recurrences in Yorkshire: final report. Lancet 1989;2:498–499.
2.
Nevin NC, Seller MJ: Prevention of neural tube defect recurrences. Lancet 1990;1:178–179.
3.
MRC Vitamin Study Research Group: Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131–137.
4.
Czeizel AE: Ten years of experience in the periconceptional care. Eur J Obstet Gynecol Reprod Biol 1999;89:43–49.
5.
Czeizel AE, Dudás I: Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327:1832–1835.
6.
Czeizel AE, Dobó M, Vargha P: Hungarian cohort controlled trial of periconceptional multivitamin supplementation shows a reduction in certain congenital abnormalities. Birth Defects Res A Clin Mol Teratol 2004;70:853–861.
7.
Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H, Li S, Moore CA, Wang H, Mulinare J, Zhao P, Wong LY, Gindler J, Hong SX, Correa A: Prevention of neural-tube defects with folic acid in China: China-US Collaborative Project for Neural Tube Defect Prevention. N Engl J Med 1999;341:1485–1490.
8.
Wills L: Treatment of ‘pernicious anaemia’ of pregnancy and ‘tropical anaemia’ with special reference to yeast extract as a curative agent. Br Med J 1931;1:1059–1064.
9.
Hoffbrand AV: The history of folic acid. Br J Haematol 2001;113:579–589.
10.
Wilcken B, Bamforth F, Li Z, Ritvanen A, Redlund M, Stoll C, Alembik Y, Dott B, Czeizel AE, Gelman-Kohan Z, Scarano G, Bianca S, Ettore G, Tenconi R, Bellato S, Scala I, Mutchinick OM, López MA, de Walle H, Hofstra R, Joutchenko L, Kavteladze L, Bermejo E, Martinez-Frias ML, Gallagher M, Erickson JD, Vollset SE, Mastroiacovo P, Andria G, Botto LD: Geographical and ethnic variation of the 677C/T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7,000 newborns from 16 areas world wide. J Med Genet 2003;40:619–625.
11.
Cuskelly GJ, McNulty H, Scott JM: Effect of increasing dietary folate on red-cell folate: implications for prevention of neural tube defects. Lancet 1996;347:657–659.
12.
Busby A, Abramsky L, Dolk H, Armstrong B, Addor MC, Anneren G, Armstrong N, Baguette A, Barisic I, Berghold A, Bianca S, Braz P, Calzolari E, Christiansen M, Cocchi G, Daltveit AK, De Walle H, Edwards G, Gatt M, Gener B, Gillerot Y, Gjergja R, Goujard J, Haeusler M, Latos-Bielenska A, McDonnell R, Neville A, Olars B, Portillo I, Ritvanen A, Robert-Gnansia E, Rösch C, Scarano G, Steinbicker V: Preventing neural tube defects in Europe: a missed opportunity. Reprod Toxicol 2005;20:393–402.
13.
CDC: Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR 1992;41:1233–1238.
14.
McPartlin J, Halligan A, Scott JM, Garling M, Weir DG: Accelerated folate breakdown in pregnancy. Lancet 1993;341:148–149.
15.
Daily LE, Kirke PN, Molloy A, Weir DG, Scott JM: Folate levels and neural tube defects. Implications for prevention. JAMA 1993;274:1698–1702.
16.
Pietrzik K, Lamers Y, Brämswig S, Prinz-Langenohl R: Calculation of red blood cell folate steady state conditions and elimination kinetics after daily supplementation with various folate forms and doses in women in childbearing age. Am J Clin Nutr 2007;86:1414–1419.
17.
Brämswig S, Prinz-Langenohl R, Lamers Y, Tobolski O, Wintergerst E, Berthold HK, Pietrzik K: Supplementation with a multivitamin containing 800 microg of folic acid shortens the time to reach the preventive red blood cell folate concentration in healthy women. Int J Vitam Nutr Res 2009;79:61–70.
18.
Wright AJ, King MJ, Finglas PM: Folate-supplemented oral contraceptives: does 6S-5-methytetrahydrofolic acid (Metafolin®) offer advantages over folic acid? Gynaecol Forum 2010;15:29–32.
19.
Prinz-Langenohl R, Brämswig S, Tobolski O, Smulders YM, Smith DE, Finglas PM, Pietrzik K: [6S]-5-methyltetrahydrofolate increases plasma folate more effectively than folic acid in women with homozygous or wild-type 677C-T polymorphism of methylenetetrahydrofolate reductase. Br J Pharmacol 2009;158:2014–2021.
20.
Pietrzik K, Bailey L, Shane B: Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2010;49:535–548.
21.
Lamers Y, Prinz-Langenohl R, Brämswig S, Pietrzik K: Red blood cell folate concentrations increase more after supplementation with [6S]-methyltetrahydrofolate than with folic acid in women of childbearing age. Am J Clin Nutr 2006;84:156–161.
22.
Williams LJ, Mai C, Edmonds LD, Shaw GM, Kirby RS, Hobbs CA, Sever LE, Miller LA, Meaney FJ, Levitt M: Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States. Teratology 2002;66:33–39.
23.
Grosse SD, Waltzman NJ, Romano PS, Mulinare J: Reevaluating the benefits of folic acid fortification in the United States: economic analysis, regulation, and public health. Am J Public Health 2005;95:1917–1922.
24.
De Wals P, Tairou F, Van Allen M, Uh SH, Lowry RB, Sibbald B, Evans JA, Van den Hof MC, Zimmer P, Crowley M, Fernandez B, Lee NS, Niyonsenga T: Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 2007;357:135–142.
25.
Wald NJ, Law MR, Morris JK, Wald DS: Quantifying the effects of folic acid. Lancet 2001;358:2069–2073.
26.
Fenech M: The role of folic acid and vitamin B12 in genomic stability of human cells. Mutat Res 2001;475:57–67.
27.
Oakley GP: Inertia on folic acid fortification: public health malpractice. Teratology 2002;66:44–54.
28.
Holzgreve W: Adding folate to the pill to prevent neural tube defects. Gynaecol Forum 2010;15:4–8.
29.
Szarevsky A: Oral contraceptive and pregnancy planning. Gynaecol Forum 2010;15:23–28.
30.
Oakley D, Sereika S, Bogue EL: Oral contraceptive pill use after an initial visit to a family planning clinic. Fam Plann Perspect 1991;23:151–154.
31.
Rosenberg MJ, Waugh MS: Oral contraceptives discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577–582.
32.
Cronin M, Schellschmidt I, Dinger J: Rate of pregnancy after using drosperinone and other progestin-containing oral contraceptives. Obstet Gyneco 2009;114:616–622.
33.
Dunson DB, Baird DD, Colombo B: Increased infertility with age in men and women. Obstet Gynecol 2004;103:51–56.
34.
Periodic health examination, 1994 update. 3. Primary and secondary prevention of neural tube defects – Canadian Task Force on the Periodic Health Evaluation. CMAJ 1994;151:21–28.
35.
Czeizel AE, Vargha P: Periconceptional folic acid/multivitamin supplementation and twin pregnancy. Am J Obstet Gynecol 2004;1891:790–794.
36.
Valek A, Béres J, Métneki J: Efficiency of prenatal screening of congenital abnormalities on the basis of the Hungarian Congenital Abnormality Registry and Surveillance. Magy Epidemiol 2010;7:S11–S12.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.